"We feel privileged and humbled to receive such extraordinary recognition for the value of our intellectual property," said Emory University President Dr. James Wagner. "These dividends will be plowed back into our mission of research and discovery for the benefit of our state, our nation and the world, in accordance with the priorities we have identified in our University-wide strategic plan."
At a Glance
Atripla®: The first and only complete HIV (Human Immunodeficiency Virus) regimen in one pill daily. ATRIPLA® is a prescription medicine used alone as a complete regimen or with other medicines to treat HIV infection in adults.
Truvada®: This section of TRUVADA.com provides information for people who are taking, or who will be taking, TRUVADA® as part of their combination HIV therapy. TRUVADA® combines two anti-HIV-1 medications, EMTRIVA® (emtricitabine 200mg) and VIREAD® (tenofovir disoproxil fumarate 300mg), into one pill that is taken once a day with or without food.
Emtriva®: Truvada® combines Emtriva® and Viread® in one tablet taken once a day in combination with other antiretroviral agents. In the United States, Truvada® is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. Safety and efficacy studies using Truvada® tablets or using Emtriva® and Viread® in combination are ongoing.
Applications In Development: